April 2023 in “Journal of Investigative Dermatology” Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
September 2019 in “Journal of Investigative Dermatology” EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.
January 2005 in “Industrial Catalysis” The process effectively regenerates the Pd/C catalyst for finasteride synthesis.
4 citations
,
July 2021 in “Skin Appendage Disorders” Sudden hair whitening may be linked to immune system activity.
2 citations
,
June 2025 in “Journal of Investigative Dermatology” CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
8 citations
,
March 2011 in “Endocrine” A new gene mutation causes vitamin D-resistant rickets and hair loss in two siblings.
130 citations
,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
30 citations
,
February 2023 in “Biomaterials Research” The hydrogel works quickly to stop bleeding and prevent infection, making it a promising first-aid bandage.
30 citations
,
September 2009 in “Seminars in Cutaneous Medicine and Surgery” Dermoscopy has greatly improved the diagnosis of skin lesions and our understanding of their morphology and biology.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
3 citations
,
March 2021 in “Journal of Pediatric and Adolescent Gynecology” Girls with Pilonidal Disease are more likely to have Polycystic Ovarian Syndrome, and treating PCOS may reduce the need for PD intervention.
3 citations
,
October 2024 in “Frontiers in Medicine” Sun-exposed skin shows different cell activity and gene expression, suggesting targets to prevent skin aging and cancer.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
1 citations
,
June 2020 in “Journal of AOAC INTERNATIONAL” Two new methods accurately measure Aminexil, Pyridoxine, and Niacinamide in hair products.
1 citations
,
January 2025 in “Dermatologic Therapy” Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
1 citations
,
April 2024 in “Journal of Cutaneous Pathology” Recurrent NICF is a rare skin condition with unclear causes, involving follicle inflammation and crystal deposits.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
October 2025 in “Pediatric Dermatology” UVFD helps quickly diagnose hair loss conditions in children.
Female rats showed more panic-related behavior than males, influenced by hormonal cycles and certain drugs.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
Higher PD-1 levels mean fewer CD8+ T cells in alopecia areata hair follicles.